HRP20190250T1 - Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije - Google Patents

Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije Download PDF

Info

Publication number
HRP20190250T1
HRP20190250T1 HRP20190250TT HRP20190250T HRP20190250T1 HR P20190250 T1 HRP20190250 T1 HR P20190250T1 HR P20190250T T HRP20190250T T HR P20190250TT HR P20190250 T HRP20190250 T HR P20190250T HR P20190250 T1 HRP20190250 T1 HR P20190250T1
Authority
HR
Croatia
Prior art keywords
newcastle disease
disease virus
attenuated newcastle
virus
cancer
Prior art date
Application number
HRP20190250TT
Other languages
English (en)
Croatian (hr)
Inventor
Xing Cheng
Danielle CARROLL
Matthew Mccourt
Mark GALINSKI
Hong Jin
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of HRP20190250T1 publication Critical patent/HRP20190250T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20190250TT 2013-09-03 2014-09-02 Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije HRP20190250T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03
PCT/EP2014/068619 WO2015032755A1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
EP14761317.8A EP3041490B1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Publications (1)

Publication Number Publication Date
HRP20190250T1 true HRP20190250T1 (hr) 2019-05-31

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190250TT HRP20190250T1 (hr) 2013-09-03 2014-09-02 Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije
HRP20220653TT HRP20220653T1 (hr) 2013-09-03 2014-09-02 Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20220653TT HRP20220653T1 (hr) 2013-09-03 2014-09-02 Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije

Country Status (25)

Country Link
US (2) US10519426B2 (enExample)
EP (3) EP3508209B1 (enExample)
JP (2) JP6557234B2 (enExample)
KR (2) KR102310692B1 (enExample)
CN (2) CN111944767A (enExample)
AU (2) AU2014317215C1 (enExample)
CA (1) CA2922071C (enExample)
CY (2) CY1121993T1 (enExample)
DK (2) DK3508209T3 (enExample)
EA (2) EA202191926A3 (enExample)
ES (2) ES2708755T3 (enExample)
HK (1) HK1231393A1 (enExample)
HR (2) HRP20190250T1 (enExample)
HU (1) HUE042382T2 (enExample)
LT (2) LT3041490T (enExample)
ME (1) ME03345B (enExample)
MX (2) MX367768B (enExample)
PL (2) PL3041490T3 (enExample)
PT (2) PT3041490T (enExample)
RS (2) RS63291B1 (enExample)
SI (2) SI3041490T1 (enExample)
SM (2) SMT202200214T1 (enExample)
TR (1) TR201902073T4 (enExample)
TW (1) TWI653334B (enExample)
WO (1) WO2015032755A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037460T2 (hu) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US20160015760A1 (en) 2013-03-14 2016-01-21 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
EA202191926A3 (ru) * 2013-09-03 2022-01-31 Медиммун Лимитед Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
CN107847610B (zh) * 2015-04-28 2022-02-01 塞维卡有限责任公司 基于piv5的扩增病毒样颗粒
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
EP3246410A1 (en) 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
WO2021189059A2 (en) * 2020-03-20 2021-09-23 Orna Therapeutics, Inc. Circular rna compositions and methods
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
US20220396809A1 (en) * 2021-06-03 2022-12-15 University Of Guelph Engineered newcastle disease virus vector and uses thereof
AU2024219190A1 (en) * 2023-02-06 2025-08-28 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses
WO2025116613A1 (ko) * 2023-11-29 2025-06-05 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
CA2383276A1 (en) * 1999-09-24 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (en) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US20160015760A1 (en) * 2013-03-14 2016-01-21 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
EA202191926A3 (ru) * 2013-09-03 2022-01-31 Медиммун Лимитед Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Also Published As

Publication number Publication date
AU2019204419A1 (en) 2019-07-11
PL3508209T3 (pl) 2022-06-13
EP4101457A1 (en) 2022-12-14
HK1225643B (en) 2017-09-15
US10519426B2 (en) 2019-12-31
CN106163532A (zh) 2016-11-23
PT3508209T (pt) 2022-05-27
JP6557234B2 (ja) 2019-08-07
EA039404B1 (ru) 2022-01-24
HRP20220653T1 (hr) 2022-06-24
CN106163532B (zh) 2019-12-31
JP2016533749A (ja) 2016-11-04
HUE042382T2 (hu) 2019-06-28
RS58332B1 (sr) 2019-03-29
AU2014317215B2 (en) 2019-03-28
SMT201900094T1 (it) 2019-02-28
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
ME03345B (me) 2019-10-20
ES2708755T3 (es) 2019-04-11
KR102285894B1 (ko) 2021-08-04
LT3508209T (lt) 2022-06-10
SI3508209T1 (sl) 2023-01-31
TR201902073T4 (tr) 2019-03-21
KR20160047570A (ko) 2016-05-02
EA202191926A2 (ru) 2021-10-29
TWI653334B (zh) 2019-03-11
CA2922071A1 (en) 2015-03-12
CY1126790T1 (el) 2024-12-13
AU2014317215C1 (en) 2019-09-12
WO2015032755A1 (en) 2015-03-12
US11471499B2 (en) 2022-10-18
CY1121993T1 (el) 2020-10-14
EP3041490A1 (en) 2016-07-13
EP3508209A1 (en) 2019-07-10
AU2019204419B2 (en) 2021-09-02
CA2922071C (en) 2022-05-03
EP3041490B1 (en) 2018-11-14
ES2914577T3 (es) 2022-06-14
AU2014317215A1 (en) 2016-04-14
LT3041490T (lt) 2019-02-25
DK3041490T3 (en) 2019-03-04
JP2019193662A (ja) 2019-11-07
EP3508209B1 (en) 2022-03-09
DK3508209T3 (da) 2022-05-30
KR102310692B1 (ko) 2021-10-12
MX367768B (es) 2019-09-05
AU2014317215A8 (en) 2016-04-21
EA202191926A3 (ru) 2022-01-31
US20200181581A1 (en) 2020-06-11
TW201606079A (zh) 2016-02-16
HK1231393A1 (zh) 2017-12-22
US20160208222A1 (en) 2016-07-21
MX2016002771A (es) 2016-09-06
PL3041490T3 (pl) 2019-05-31
CN111944767A (zh) 2020-11-17
KR20210048605A (ko) 2021-05-03
RS63291B1 (sr) 2022-06-30
JP6862500B2 (ja) 2021-04-21
SMT202200214T1 (it) 2022-07-21
EA201690425A1 (ru) 2016-08-31
MX2019010364A (es) 2019-10-07

Similar Documents

Publication Publication Date Title
HRP20190250T1 (hr) Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije
JP2019193662A5 (enExample)
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
JP2016533749A5 (enExample)
HRP20240078T1 (hr) Imuno-onkolitičke terapije
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
HRP20231025T1 (hr) Onkolitički virus vakcinije
WO2015017527A3 (en) Methods for the production of long length clonal sequence verified nucleic acid constructs
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
EA202191602A3 (ru) Не содержащая сыворотки среда для культивирования клеток
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
EA201891471A1 (ru) Композиции фосфорамидатных производных нуклеозидных лекарственных средств
DK3981414T3 (da) Lyofiliserede præparater med højt overfladeareal, der indeholder arsenik til oral indgivelse i patienter
MX2019005102A (es) Poxvirus quimericos sinteticos.
WO2014169882A3 (zh) 具有抗肿瘤活性的苯并咪唑类化合物、制备方法及其应用
CL2017001088A1 (es) Regimen de dosificación para interferón pegilado
PH12018500463A1 (en) Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
Abdolreza et al. < The> effect of endurance training on MiR-155 expression, STAT3 gene expression, and interleukin 6 protein in mice with breast cancer
CN103653183A (zh) 一种口服液防腐保鲜剂
de la Educación TOMO 17
MX2019013161A (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
AR118181A2 (es) Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
Jeon Anti-gd2 monoclonal antibody (dinutuximab) with gm-csf, interleukin 2, and cis-retinoic acid for the treatment of high-risk neuroblastoma